Back to the future: a recent history of haemophilia treatment.

Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Blood Transfus (2010) 1.24

Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus (2010) 1.19

Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus (2011) 1.13

A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia. Nat Biotechnol (2011) 1.12

Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol (2011) 1.09

Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis (2012) 1.07

Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med (2010) 1.07

The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfus (2013) 1.05

The modern treatment of haemophilia: a narrative review. Blood Transfus (2012) 0.91

Recombinant factor VIII in the management of hemophilia A: current use and future promise. Ther Clin Risk Manag (2009) 0.86

Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector. Blood (2009) 0.85

Uncovered needs in the management of inherited bleeding disorders in Italy. Blood Transfus (2014) 0.84

Murine leukemia virus-derived retroviral vector has differential integration patterns in human cell lines used to produce recombinant factor VIII. Rev Bras Hematol Hemoter (2014) 0.84

Epidemiology & social costs of haemophilia in India. Indian J Med Res (2014) 0.82

Revisiting hemophilia management in acute medicine. J Emerg Trauma Shock (2011) 0.82

Treatment of hemophilia B: focus on recombinant factor IX. Biologics (2013) 0.81

Clinical use of factor VIII and factor IX concentrates. Blood Transfus (2013) 0.80

Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin. Protein J (2014) 0.79

Design and characterization of an APC-specific serpin for the treatment of hemophilia. Blood (2016) 0.79

Prophylaxis in congenital coagulation disorders: past, present and future. Blood Transfus (2008) 0.78

Emerging and future therapies for hemophilia. J Blood Med (2015) 0.77

Continuing education course #2: current understanding of hemostasis. Toxicol Pathol (2010) 0.76

Lack of evidence of neoantigen formation in different batches of a double-virus inactivated factor VIII concentrate manufactured in Argentina. Blood Transfus (2010) 0.75

Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. PLoS One (2017) 0.75